# DelveInsight Report Tracks 100+ BCMA-Targeted Therapies From 80+ Drugmakers

> DelveInsight's 2026 BCMA report covers more than 100 pipeline therapies from over 80 players, with 8+ in late-stage development for multiple myeloma and other diseases.

- Published: 2026-11-12T18:24:42+00:00
- Section: Research & Clinical Trials
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-12/delveinsight-bcma-therapies-report
- Source: [GlobeNewswire](https://www.globenewswire.com/news-release/2026/11/12/3402074/0/en/bcma-targeted-therapies-competitive-landscape-analysis-100-pipeline-therapies-driving-innovation-in-therapeutics-segment-delveinsight.html)

## Key takeaways

- DelveInsight's 2026 report covers more than 100 pipeline BCMA-targeted therapies from over 80 active players.
- About 8+ BCMA-targeted therapies are in late-stage development, while 35+ are in mid and early stages.
- Cartesian Therapeutics' Descartes-08 is listed at Phase III for myasthenia gravis in the report's pipeline snapshot.

[DelveInsight](https://akta.pro/company-profiles/00056iy/delveinsight) released a 2026 competitive landscape report covering more than 100 pipeline BCMA-targeted therapies from over 80 active players, with about 8+ candidates in late-stage development. The New York-based research firm announced the report on November 12, 2026, according to [GlobeNewswire](https://www.globenewswire.com/news-release/2026/11/12/3402074/0/en/bcma-targeted-therapies-competitive-landscape-analysis-100-pipeline-therapies-driving-innovation-in-therapeutics-segment-delveinsight.html).

## What DelveInsight's BCMA Report Covers

DelveInsight is a life sciences market research and consulting firm founded in 2014 and headquartered in New Delhi, according to company records. The BCMA report spans approved and pipeline therapies across clinical stages, with analysis of trial benchmarking, partnering and licensing activity, and FDA and EMA regulatory pathways.

The report counts 35+ drugs in mid and early stages of development. Indications under study include multiple myeloma, myasthenia gravis, systemic lupus erythematosus and systemic sclerosis. Named developers include Regeneron Pharmaceuticals, Pfizer, AstraZeneca, [Cartesian Therapeutics](https://akta.pro/company-profiles/00035z3/cartesian-therapeutics), [Caribou Biosciences](https://akta.pro/company-profiles/0000b56/caribou-biosciences), Gilead Sciences, AbbVie and Johnson & Johnson.

Stuti Mahajan, Functional Head of Consulting at DelveInsight, said that BCMA-targeted therapies have emerged as a key treatment approach in multiple myeloma, with CAR-T cell therapies and bispecific antibodies demonstrating meaningful clinical activity, particularly in heavily pretreated patients. Mahajan said challenges related to treatment resistance, relapse, toxicity, manufacturing complexity, and patient access remain.

## DelveInsight's Research Output

DelveInsight has scaled its report repository to over 7,000 research reports spanning 27 therapeutic areas, according to akta.pro [company records](https://akta.pro/company-data). The same records list more than 1,000 clients across pharmaceutical, biotech and healthcare sectors and more than 500 completed consulting projects. In March 2026 the firm launched DelveEpiAI, an AI-powered epidemiology database covering 500+ disease indications with 10-year forecasts across the seven major markets.

## Earlier DelveInsight Pipeline Reports

DelveInsight published a 2026 report on GLP-1 receptor agonists and incretin-based therapies covering over 200 pipeline drugs from more than 180 companies, GlobeNewswire reported in November 2026. GlobeNewswire also reported the firm's 2026 sickle cell disease pipeline report, covering 45+ companies developing 50+ drugs, with about 5 in late-stage development. In October 2026, openPR.com reported DelveInsight's market report on invasive pneumococcal disease, covering vaccines and therapeutics across the 7MM.

## BCMA Trial Readouts Ahead

The report cites October 2026 topline results from Pfizer's Phase III MagnetisMM-32 study of elranatamab as monotherapy in relapsed or refractory multiple myeloma and AbbVie's October 2026 BLA submission to the FDA for etentamig. It also notes Vyriad's September 2026 IND clearance for VV169 and IASO Biotechnology's September 2026 first-in-human Phase I data for IASO206.

## Companies in this story

- [DelveInsight company profile](https://akta.pro/company-profiles/00056iy/delveinsight) · website: https://www.delveinsight.com
- [Cartesian Therapeutics company profile](https://akta.pro/company-profiles/00035z3/cartesian-therapeutics) · website: https://www.cartesiantherapeutics.com
- [Caribou Biosciences company profile](https://akta.pro/company-profiles/0000b56/caribou-biosciences) · website: http://www.cariboubio.com

---
News for Agent · https://newsforagent.com/llms.txt